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LITERATURE REVIEW

A Study Of Multiple Sclerosis
Christine Chen1
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The University of Louisville, Louisville, KY, USA

Autoimmune diseases are diseases in which the immune
system starts attacking itself. The immune system
defends the body from pathogens such as bacteria and
viruses by recognizing antigens on these pathogens.
Usually, the immune system can recognize itself and
develop tolerance to prevent it from attacking itself.
However, there are instances where the immune system
loses tolerance and starts attacking itself, leading to
autoimmune disease. Multiple Sclerosis is an
autoimmune disease in which the immune system
attacks the central nervous system.
The immune system comprises two system types: the
innate immune system and the adaptive immune system.
The innate immune system is the first line of defense
when a pathogen enters the body and can generate the
same response regardless of the type of pathogen. On the
other hand, the adaptive immune system is more
specialized, taking a few days to weeks to be activated.
Once activated, adaptive immune cells can target that
specific pathogen and result in a faster response if
encountered again. T and B cells are part of the adaptive
immune system and have unique development and
activation. Both the T and B cells originate from the bone
marrow; however, the T cells go to the thymus to finish
development, while B cells finish their development in
the bone marrow.
The activation of T cells differs from B cells in that they
need be presented with an antigen via antigenpresenting cells (APCs). APCs such as macrophages and
dendritic cells can recognize pathogens via pathogenassociated molecule patterns (PAMPs) or damaged cells
via damage-associated molecule patterns (DAMPs). The
APCs would bind to PAMPs or DAMPs via pattern
recognition receptors such as toll-like receptors and Ctype lectin receptors. These receptors are located either
on the outside or inside a cell and can bind to specific
pathogens depending on PAMPs and the location of the
PAMPs. Once activated, the APCs would phagocytose
these molecules and present them on the major
histocompatibility complex (MHC).
There are two types of MHC, MHC Class I and MHC
Class II. The type of MHC produced depends on the
pathway. The endogenous pathway produces MHC class
I and can only bind to CD8+ cytotoxic T cells, while the
exogenous pathway produces MHC class II and can only
bind to CD4+ helper T cells. Costimulatory molecules are
also required for T cells to become activated when
binding to MHC. These costimulatory molecules are
CD28 on T cells and CD80/86 on APCs. There are also

coinhibitory molecules that prevent T cells from
becoming activated. With both MHC and costimulatory
molecules, T cells can become activated and go through
positive and negative selection in the thymus.
During the development of T and B cells, they go through
positive and negative selection. Positive selection is
where the T and B cells are tested to see if they can
engage with self-antigen. If they do not engage with selfantigen, they will die due to a lack of stimulation from
other cells, such as antigen-presenting cells. Negative
selection is where the T and B cells are tested to see if
they bind too strongly to the self-antigen. If they do, then
they die via apoptosis. In the thymus, the T cells are
presented with antigens from the body to test for
negative selection. The antigens presented from all over
the body are from medullary thymic epithelial cells
(mTECs). mTECs have a protein, AIRE, that allows
mTECs to express, process, and present proteins found
in specific organs. They bind to epigenetic marks on
histones and recruit transcription factors to allow RNA
polymerase to access the area. This process can prevent
self-reactive T cells from leaving the thymus and
circulating in the body. B cells do not have this
mechanism because B cells require helper T cells to
become activated. If there is a self-reactive B cell, it will
need a helper T cell that is also self-reactive, but due to
negative selection in the thymus, T cells would have died
from apoptosis.
Negative selection results in central tolerance, where our
T and B cells can recognize themselves but react against
it. Without negative selection, T and B cells will react too
strongly to themselves, leading to autoimmunity.
Peripheral tolerance occurs when some of the selfreactive T or B cells manage to escape selection and
enter the periphery. Peripheral tolerance induces T and
B cell anergy. Cell anergy is when the cells become
unresponsive to stimulus and can occur when binding to
cells without the costimulatory molecules or binding to
cells but a coinhibitory molecule bind to the cell instead
of a costimulatory molecule. Some self-reactive T cells
that escape to the periphery become regulatory T cells
(Treg) which down-regulates inflammation by inhibiting
APCs and T cells.
Multiple Sclerosis (MS) is an autoimmune disease that
attacks the central nervous system (CNS) – brain, and
the spinal cord. It causes chronic inflammation in the
CNS that leads to demyelination and neurodegeneration
(Correale et al., 2017). This disease primarily affects
young adults, mainly women, and over two million are
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affected worldwide. (Garg & Smith, 2015) The cause of
MS is unknown; however, it is believed to be triggered by
genetic and environmental factors. Some genetic factors
that have been identified are the interleukin-2 receptor
alpha gene and the interleukin-7 receptor alpha genes.
Environmental factors that have been linked to MS are
the Epstein-Barr virus (EBV) and vitamin D deficiency
(Garg & Smith, 2015). Studies have shown that MS is
prevalent in populations living further away from the
equator, correlating with the increasing vitamin D
deficiency. Immigrants from countries near the equator
that moved further away from the equator, such as
Europe, have a lower risk of developing MS; however,
children from those immigrants living in Europe have a
higher chance of developing MS (Dobson & Giovannoni,
2018).
Multiple Sclerosis is caused by the loss of self-tolerance,
where our immune system would not recognize
myelin antigen and attack it. This loss of self-tolerance
could be triggered by an environmental factor such
as EBV infection. When EBV infects the body, it can
trigger a release of autoantigens due to damage to the
cell. The autoantigen can lead to the molecular
mimicry
or bystander activation of T cells.
Molecular mimicry is when a foreign antigen, in this
a virus antigen, shares similarities with the myelin
antigen. In terms of MS, the immune system can
secrete antibodies that attacks the EBV nuclear
antigen EBNA1. However, this can cross-react with
glial cell adhesion proteins on the CNS, creating T
and B cells that are specific for those antigens. Studies
have shown in where patients with MS anti-glial cell
adhesion proteins antibodies have, supporting the
idea that molecular mimicry between the EBNA1 antigen
and host glia cell adhesion protein contributes to
the development of MS (Dempsey, 2022).
Bystander activation of T cells are T cells activated in a T
cell receptor-independent and cytokine-dependent
manner (Kim & Shin, 2019). So, when there is a viral
infection such as EBV, it can cause the body to release
series of cytokines to attack the virus. In doing so, these
cytokines can activate myelin antigen specific T cells, in
this case, MS. These cells do not have specificity for the
pathogens, but they can still participate in the immune
response by secreting cytokines or exerting cytotoxicity.
Some studies have shown that activation of NK, NKT and
dendritic cells in response to virus such as murine
cytomegalovirus can cause the release of IL12 and IFN-γ.
These cytokines can result in the bystander activation of
antigen specific T and B cells in MS and other
autoimmune diseases (McCoy et al, 2006).
Once these CNS reactive T cells are activated in the body,
they can enter the CNS through the blood-brain barrier.
This migration involves the interaction between very late
antigen-4 (VLA-4) on the T cells and the vascular cell
adhesion molecule-1 (VCAM-1) on capillary endothelial
cells (Garg & Smith, 2015). Once these T cells enter the
CNS, they will react with the antigens in the brain.
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CD8+ T cells play a significant role in this response by
binding to antigen presented by MHC class I receptor on
the antigen-presenting cells. (APC) The CD4+ T cells also
play a role, binding to APC presenting the myelin antigen
on MHC class II receptors (Garg & Smith, 2015). This
binding can trigger an inflammatory cascade, releasing
cytokines
and
chemokines,
recruiting
more
inflammatory cells, and increasing inflammation. This
constant inflammation results in demyelination of the
myelin sheath on axons. The pro-inflammatory cytokines
are released by CD4+ TH1 cells, such as interferongamma, IL-2, and TNF-alpha. Another subset of CD4+ T
cells like TH17 plays a role in inflammation by secreting
IL-17. Due to high levels of TH1 T cells, it downregulates
TH2, which secretes interleukin 4, 5, and 10, limiting the
effects of TH1 cell response (Garg & Smith, 2015). This
downregulation of TH2 can increase pro-inflammatory
responses.
While T cells play a huge in MS, there has been evidence
that B cells play a role in MS. There has been recent
evidence of clonal B cell proliferation in both the CNS
and the rest of the body (Alroughani & Yamout, 2018).
Follicle structures have been found in the meninges,
containing proliferating B cells, helper T cells, and
follicular dendritic cells. The follicular dendritic cells in
these follicles are shown to secrete CXCL13 which
recruits B cells into the area (Correale et al., 2017). Due
to B cell proliferation, it can maintain meningeal
inflammation by producing the antibody, secreting
cytokine, presenting antigen, and forming follicle
structures.
Both T and B cell activity leads to demyelination and
early axonal injuries by directly attacking myelin and
oligodendrocytes and secretion of antibodies. CD8+ T
cells can bind to MHC I on APC which can induce axonal
injuries, but the exact mechanism is not clear (Garg &
Smith, 2015). Myelin and oligodendrocytes can also
indirectly be affected by the pro-inflammatory cytokines
such as IL6, IL22 and TNF-alpha. IL6 can encourage the
differentiation of effector T cell and down regulate Treg.
Some studies have shown that IL22 can trigger
oligodendrocytes to express Fas expression, increasing
apoptosis. (Vani & Chitra, 2022) So, treatments have
been designed to target T and B cells and limit the proinflammatory cytokines; however, the exact mechanism
of these treatments is yet to be understood.
The main form of treatment is the immunomodulatory
therapies (IMT) which include a variety of medications
to suppress the immune response caused by autoreactive
lymphocytes. One treatment of IMT is using beta
interferon (Garg & Smith, 2015). Beta-interferons can
stabilize the blood-brain barrier, thus limiting T cells
from entering the CNS, modulating T and B cell
functions, and altering the expression of cytokines (Garg
& Smith, 2015). Once beta-interferon binds to cell
receptors, it can increase the expression of antiinflammatory cytokines such as IL-10 and IL-4. It can
also shift from TH1/Th17 towards TH2 antiinflammatory response (Filipi & Jack, 2019).
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There are a variety of interferon-beta therapies that the
FDA has approved, and their efficacy can vary depending
on the dosage and frequency of injection of the drug.
The other form of treatment is using glatiramer acetate
(GA), a synthetic complex of four amino acids similar to
myelin basic protein (Garg & Smith, 2015). Studies have
shown that GA upregulates differentiation of CD4+ T
cells into TH2 cells, downregulates TH17 differentiation,
and increases the frequency of regulatory T cells
(Häusler et al., 2022). The increase in regulatory T cells
allows for an increase in anti-inflammatory cytokines. It
also played a huge role in decreasing B cell activation
and differentiation while increasing IL-10 secretion and
MHC class II expression. Increasing IL-10 secretion
decreases the production of a pro-inflammatory cytokine
such as TNF-alpha (Häusler et al., 2022).
Multiple Sclerosis is an autoimmune disease that affects
people between the ages of 20 and 40 years. While its
exact cause is unknown, several genetic and
environmental factors have been identified that can
increase susceptibility to the disease, including Vitamin
D deficiency and EBV. Multiple Sclerosis affects the CNS,
resulting
in
T
cells
attacking
myelin
and
oligodendrocytes. Combined with constant inflammation
by pro-inflammatory cytokines and B cells, these attacks
damage neurons in the CNS, resulting in loss of brain
function and leading to cognitive and emotional deficits.
Treatments have been created to lessen the T and B cells'
effect and upregulate the production of antiinflammatory cytokines. More research is needed to
understand the exact mechanism and role of B and T
cells in MS, and through that, better treatment can
become more available.
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